Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
Open accessThe DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
With the success of immune checkpoint inhibitors (ICIs), significant progress has been made in the field of cancer immunotherapy. Despite the long-lasting outcomes in responders, the majority of patients with cancer still do not benefit from this revolutionary therapy. Increasing evidence suggests that one of the major barriers limiting the efficacy of immunotherapy seems to coalesce with the hypoxic tumor microenvironment (TME), which is an intrinsic property of all solid tumors. In addition to its impact on shaping tumor invasion and metastasis, the hypoxic TME plays an essential role in inducing immune suppression and resistance though fostering diverse changes in stromal cell biology. Therefore, targeting hypoxia may provide a means to enhance the efficacy of immunotherapy. In this review, the potential impact of hypoxia within the TME, in terms of key immune cell populations, and the contribution to immune suppression are discussed. In addition, we outline how hypoxia can be manipulated to tailor the immune response and provide a promising combinational therapeutic strategy to improve immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MICA is the ligand for Natural killer group 2 member D (NKG2D), the activating receptor that promotes tumor elimination by NK and CD8+ T cells.”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Soluble MICA downregulates the NKG2D activating receptor on NK and T cells, facilitating tumor cell escape (Fig. 2C) [83].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [83]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, HIF-1α upregulates a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) in tumor cells, which promotes the shedding of Major histocompatibility complex class I chain related molecule (MICA) from the surface of tumor cells.”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Metabolic regulation of gene expression by histone lactylation
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1678-1 · Cited by 4,371
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“M2-like polarization of TAMs, which is partly mediated by HIF-1α activation [58].”
BackgroundTop 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · cited 1×
“Substantial cellular stress caused by the hypoxic TME promotes the heterogeneity and plasticity of tumors and contributes to the development of more invasive and therapeutically resistant tumor phenotypes [4].”
BackgroundEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 2×
“TAMs constitute the primary immune cell infiltrate in the TME of solid tumors [55].”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Self-citationChallenges in developing personalized neoantigen cancer vaccines
Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00937-y · Cited by 258
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Hypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Perez-Ruiz, E., Sarmento-Ribeiro, A. B., Saponara, S., De Las Rivas, J., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 246
Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy
Liang, S., Yao, J., Liu, D., Rao, L., Chen, X., & Wang, Z. (2023) · Advanced Materials · doi:10.1002/adma.202211130 · Cited by 243
Metadata
- Authors
- Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X.
- Affiliations
- Jilin University (CN)
- Moffitt Cancer Center (US)
- Corresponding author
- Xin, Ying
- Jiang, Xin
- ORCID
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2021-01-09
- Volume
- 40
- Issue
- 1
- Pages
- 24-24
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC7796640
- OpenAlex
- W3118395892
- Semantic Scholar
- eca6d9ec297cd850410f4d6c8325e834f1f6bf62
- Cited by
- 315
- References
- 111
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 70 · 2023: 54 · 2022: 71 · 2021: 33
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- the National Natural Science Foundation of China (81570344)
- National Key R&D Program of China (2017YFC0112100)
- the Education Department Foundation of Jilin Province (JJKH20201036KJ)
- the Health and Family Planning Commission of Jilin Province Foundations (2016Q034 and 2017J11)
- the Norman Bethune Program of Jilin University (2015225 and 2015203)
- Jilin Scientific and Technological Development Program (20180414039GH and 20190201200JC)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- tumor hypoxia, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, immunosuppression, immune evasion, stromal cells, immune cell subsets, combination therapy, tumor invasion and metastasis
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Cell Hypoxia, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s13046-020-01820-7
- The paper
- Wang, B., Zhao, Q., Zhang, Y., Liu, Z., Zheng, Z., Liu, S., Meng, L., Xin, Y., & Jiang, X. (2021). Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-020-01820-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.